A novel polyplex nanoparticle formulated at the NCL is shown to inhibit growth of pancreatic cancer and prevent metastasis in mice. The study was co-lead by Dr.
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program.
The NCL has just launched two new Technical Services to measure drug release from nanomedicines—ideal for assessing bioequivalence of complex drugs.